QUEBEC CITY, April 29, 2013 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR)
(OTCQX: DGCRF) is pleased to announce that Dr. Yves Fradet, Dr. Louise
Proulx, Mr. Andrew Sheldon, Dr. Jacques Simoneau, and Dr. Vincent R.
Zurawski, were re-elected by shareholders at the 2013 annual and
special meeting of shareholders, held today in Montreal.
Shareholders also reappointed Ernst & Young as auditors of the company,
approved and ratified amendments to the articles of DiagnoCure,
approved and ratified the new by-laws of the company - including the
advanced notice by-law, and approved all unallocated options under
DiagnoCure's stock option plan.
Dr. Yves Fradet, Chairman of the Board stated, "We appreciate the
support of our shareholders in re-electing all of DiagnoCure's director
nominees. Rest assured, your board and management team will continue to
work to enhance and maximize value for shareholders."
"We will continue to be receptive to feedback from all of our
shareholders." said Dr. Fradet.
The election results for the Board of directors are as follows:
|
|
For
|
Withheld
|
|
DiagnoCure nominees
|
|
|
|
Yves Fradet
|
15,064,450
|
11,584,571
|
|
Louise Proulx
|
15,195,476
|
11,573,041
|
|
Andrew J. Sheldon
|
15,155,676
|
11,612,841
|
|
Jacques Simoneau
|
15,194,976
|
11,573,041
|
|
Vincent R. Zurawski
|
15,167,576
|
11,600,941
|
|
|
|
|
|
Dissident nominees
|
|
|
|
Pierre Dozois
|
5,385,250
|
22,797,322
|
|
Paul Guay
|
5,385,250
|
22,797,322
|
|
Hans Mäder
|
5,385,250
|
22,797,322
|
|
|
|
|
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is
currently available for licensing. The Corporation has granted a
worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary
of Hologic Inc. operating as Hologic Gen-Probe, for the development and
commercialization of a prostate cancer test using PCA3, DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3
test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and the United States. For more
information, please visit www.diagnocure.com.
Forward‐looking statements
This release may contain forward‐looking statements that involve known
and unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates", "assumes",
"believes", "estimates", "expects", "intend", "may", "plans",
"projects", "should", "will", or the negative thereof or other
variations thereon. Forward-looking statements also include any other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the "safe-harbour"
provisions of applicable Canadian securities laws. By their very
nature, forward‐looking statements are based on expectations and
hypotheses and also involve risks and uncertainties, known and unknown,
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors and
others in understanding certain key elements of the Corporation's
current objectives, strategic priorities, expectations and plans, and
in obtaining a better understanding of the Corporation's business and
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes and that they
should not place undue reliance on these forward‐looking statements.
For instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based on
management expectations and such outcome may vary materially depending
on global political and economic conditions, dependence on
collaboration partners, uncertainty of healthcare reimbursement, and
marketing and distribution challenges. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly update
or revise any forward‐looking statements contained herein unless
required by the applicable securities laws and regulations.
SOURCE: DiagnoCure inc.
